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ABSTRACT 
Antibiotic resistance is a current threat to modern medicine. Not only is it 
challenging to treat but it also adds considerable costs to the healthcare 
systems. At the current rate of rising drug resistance, approximately 10 million 
people will die annually by 2050. The World Health Organization (WHO) has 
listed the six most threatening pathogens for which new antibiotics and 
approaches are urgently needed. One of the fastest evolving and most 
notorious Gram-positive bacteria in the list is Staphylococcus aureus. In 
addition to developing resistance to a vast number of antibiotics, this 
bacterium can attach to surfaces and form biofilms. This lifestyle allows 
bacteria to protect themselves from the immune system and impairs treatment. 
Thus, new innovative approaches and antibacterial agents are needed to fight 
bacterial resistance. 
As microbial adhesion is the first step of biofilm formation, the first aim of 
this study was to develop novel antibacterial surfaces to hamper the 
accumulation of antibiotic-resistant microbes. Cellulose is the most abundant 
natural polymer with various appealing characteristics. It is renewable, 
biocompatible, biodegradable, and possesses excellent mechanical 
properties. Cellulose nanofibers are prepared by mechanical disintegration of 
cellulose. Thin films of cellulose nanofiber can be prepared, and their surface 
can be modified to provide cellulose with new properties. 
Terpenoids such as abietic acid and dehydroabietic acid originating from 
conifer resin possess antibacterial and antifungal activities. We have 
previously shown that the amino acid-bearing derivatives of dehydroabietic 
acid possess antimicrobial properties. 
Herein, I report the design and the synthesis of new wide-spectrum contact-
active non-leaching antibacterial cellulose nanofiber films by coupling the films 
with dehydroabietylamine, dehydroabietic acid and their derivatives. Different 
techniques and measurements were used to study the new biomaterials 
including contact angle (CA), streaming current measurements, X-ray 
photoelectron spectroscopy (XPS), atomic force microscopy (AFM), oxygen 
transmission rate (OTR), water vapor transmission rate (WVTR), scanning 
electron microscope (SEM), tensile strength, and Young’s modulus. 
Our unique design rendered four anionic surfaces highly active against the 
Gram-positive S. aureus, including the drug resistant methicillin-resistant 
Staphylococcus aureus (MRSA) and the Gram-negative Escherichia coli. The 
proposed modes of action and the fact that the compounds are based on a 
new chemical class account for a low potential to spread resistance. 
Our most active material 87 was tested against bacterial colonization in 
both biofilm and artificial dermis models. The bacterial colonization was 
efficiently prevented in both models. Material 87 proved to be biocompatible 
as it nurtured fibroblast growth at its surface without causing significant 
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hemolysis. Our originally designed surfaces represent a new class of 
renewable biomaterials suitable for biomedical applications. 
The second aim of this thesis was to develop a new class of pyrimidine 
derivatives against S. aureus biofilms. From our novel set of pyrimidines, 
compounds 89, 99e, and 100e displayed potent activities. They inhibited 
biofilm formation and were active against pre-formed biofilms of S. aureus 
ATCC 25923 and Newman strains with IC50 values ranging between 11.6 to 
62.0 μM. The compounds were also effective against planktonic cells with 
minimum inhibitory concentration (MIC) values lower than 60 μM. Only 
marginal cytotoxicity was revealed against human Hep2 cells at 
concentrations comparable to their pre-exposure IC50 values. 
Overall, this study resulted in the synthesis of four new antibacterial 
biomaterials and 26 new pyrimidine derivatives. This thesis offers novel 
approaches to target one of the most dangerous antibiotic-resistant bacteria 
S. aureus and efficiently limit its proliferation. 
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1.1 NEED FOR NEW ANTIMICROBIALS 
The emergence of antimicrobial resistance (AMR) has accelerated over the 
last decade.1 Globally, 700,000 patients die every year of resistance-related 
infections, while in Europe, 33,000 patients die annually because of antibiotic-
resistant bacteria.2 At the current rate of rising drug resistance, approximately 
10 million deaths will occur annually by 2050. That will translate into a global 
economic loss of about USD 100 trillion. A study by Chandy et al. revealed 
that patients with antibiotic-resistant infections pay USD 700 more than 
patients who can be treated with first-line antibiotics in India.3 
In April 2014, the World Health Organization (WHO) published the first 
global report on antibiotic resistance. The report explained the current situation 
about the high rates of resistance and stressed that urgent attention is required 
to avoid the “post-antibiotic era”.4 
Antibiotics are antibacterial drugs that kill or slow down the growth of 
bacteria and are used to prevent and treat bacterial infections.5 They act 
through various mechanisms of action. They can have an effect on the 
synthesis of proteins, bacterial cell, ribonucleic acid (RNA), and 
deoxyribonucleic acid (DNA) or have other specific actions.6 
Scientists discovered most of the currently used antibiotics during the 
period of 1940-1970 from natural extracts of microorganisms.7 Since the 
discovery of penicillin in 1928, antibiotics have been used beyond treating 
simple infections. Healthcare professionals used antibiotics in complex 
medical approaches such as organ transplantations, management of cancer 
patients and surgical procedures.8 Antibiotics extend life spans by decreasing 
the morbidity caused by food-borne and poverty-related infections.9 
Antimicrobial resistance emerges when antibiotics lose their effect to 
prevent the growth of bacteria, i.e., bacteria keep on multiplying and growing 
in the presence of the antibiotic.10 Unfortunately, resistance has developed to 
almost all antibiotics known to humans, and to date there are no methods 
available to reverse the process of antimicrobial resistance.11 To address this 
problem, new antimicrobial agents are needed. 
The only novel class of antimicrobial compounds discovered in the past 40 
years is the oxazolidinones represented by linezolid, released in 2000.12 Soon 
after reaching the market, studies identified clinical isolates of Staphylococcus 
aureus and several Enterococcus species that were resistant to linezolid.13 
Most of the new antimicrobial agents are analogues of the known compound 
classes to which resistance has already been developed. Resistance can 
occur to structurally similar compounds. For example, resistance to 
tetracycline may incur resistance to minocycline, doxycycline, 
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chlortetracycline and oxytetracycline.14 On average only every fifth compound 
in clinical trials will reach the market. 
1.2 MECHANISMS OF ANTIMICROBIAL RESISTANCE 
 
Bacteria use various mechanisms to resist the effect of antibiotics. They 
can alter or inactivate antibiotics, modify the drug binding site or change cell 
permeability.15 
Many bacteria produce enzymes such as β-lactamases, aminoglycoside-
modifying enzymes, or chloramphenicol acetyltransferases to modify or 
inactivate antibiotics. For example, the Gram-negative E. coli and P. 
aeruginosa developed resistance to β-lactam antibiotics by producing β-
lactamases, which hydrolyze the β-lactam ring present in many antibiotics 
such as penicillins, cephalosporins, monobactams, and carbapenems. 
Other bacteria modify their target site to avoid recognition by antibiotics.15 
They do this, for example, by modifying genes that encode binding proteins. 
Penicillin-binding proteins (PBPs) are enzymes anchored on the cytoplasmic 
membrane of the bacterial cell wall. They are involved in the synthesis of 
peptidoglycan, an essential component of the bacterial cell wall. S. aureus can 
mutate the genes encoding PBPs to form unique penicillin-binding proteins, 
for example, PBP2a. This mutated protein has a lower affinity for β-lactam 
antibiotics such as methicillin, which inhibits the synthesis of bacterial cell 
walls. PBP2a is the most dominant PBP form in the methicillin-resistant 
Staphylococcus aureus (MRSA). Mutated genes can be inherited genetically 
from mother to daughter bacteria.10 
Reduction of antibiotic permeability is another strategy used by bacteria to 
develop antibiotic resistance.15 The bacterial cell envelope has a complex 
structure that regulates the molecular traffic between the cell and its 
environment. The cell envelope of Gram-negative bacteria differs from that of 
Gram-positive bacteria. It consists of an outer membrane followed by a 
peptidoglycan cell wall and an inner cell membrane (Figure 1).16 The outer 
membrane is a distinguishing feature of Gram-negative bacteria and is lacking 
in Gram-positive bacteria. The outer membrane is composed of glycolipids 
mainly lipopolysaccharide. The lipid portion acts as endotoxin and can trigger 
various life-threatening physiological reactions in humans. The main function 
of the outer membrane is to act as a protective barrier making Gram-negative 






Figure 1 Difference in cell envelope between Gram-positive and Gram-negative 
 bacteria. LPS, lipopolysaccharide; WTA, wall teichoic acid; LTA, lipoteichoic acid 
 (adapted from Silhavy et al. 2010).16 
The outer membrane of Gram-negative bacteria contains proteins known 
as porins.15 These proteins provide aqueous channels and facilitate the 
passive transport of small hydrophilic antibiotics. P. aeruginosa developed 
resistance to the antibiotic imipenem by reducing the expression of porin 
protein OprD which reduced drug influx into the cell. Acinetobacter baumannii 
became resistant to the antibiotics imipenem and meropenem by decreasing 
the expression of 29 kDa outer membrane protein. This protein is involved in 
transporting molecules across the outer membrane of the bacteria. 
Antibiotics larger than 600 Da, such as vancomycin and daptomycin, 
cannot penetrate the envelope of Gram-negative bacteria.17 Thus, the outer 
membrane of Gram-negative bacteria hampers the development of novel 
antibiotics. 
The main part of the cell envelope found in both Gram-positive and Gram-
negative bacteria is the peptidoglycan layer.16 As Gram-negative bacteria are 
gifted with the outer membrane, their peptidoglycan layer is relatively thin 
consisting of one to few layers and is few nanometers thick. On the contrary, 
Gram-positive bacteria have thick and multi-layered peptidoglycan, around 
30–100 nm thick. Within their thick peptidoglycan layer, Gram-positive bacteria 
have long anionic polymers known as teichoic acids. They are composed 
mainly of glycerol phosphate, glycosyl phosphate, or ribitol phosphate repeats 
and account for 60% of the mass of the cell walls of Gram-positive bacteria. 
They are divided into two main groups, wall teichoic acids, covalently attached 
to peptidoglycan, and lipoteichoic acids, attached to the head groups of 
membrane lipids. 
In addition to teichoic acids, the surfaces of Gram-positive bacteria contain 
a variety of proteins.15 As these bacteria lack an outer membrane to contain 
extracellular proteins, all the proteins exist in or near the membrane. The 
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peptidoglycan layer is a target for many antibiotics, which cause cell lysis. 
However, bacteria can protect themselves by inactivating the antibiotics, as in 
the case of producing -lactamases to target β-lactam antibiotics. 
Efflux pumps are transport proteins localized in the cell membrane of both 
Gram-positive and Gram-negative bacteria.18 They are used by bacteria to 
remove antibiotics from their intracellular compartment. Most of the efflux 
pumps are multidrug transporters able to expel a wide range of antibiotics at 
a high rate. The synergistic effect of the outer membrane barrier and the efflux 
pumps is a key for resistance in many bacteria.15 For example, multidrug-
resistant Enterobacter aerogenes overexpresses its AcrAB efflux pumps and 
simultaneously decreases the expression of porins. This results in lower 
antibiotic permeability and more effective resistance. 
Bacteria have developed various antibiotic resistance mechanisms. The 
main mechanisms include modification of drug targets, enzymatic inactivation, 
and limiting cell permeability through porin loss or overexpression of efflux 
pumps. Bacteria can resist a wide range of antibiotics by developing multiple 
resistant mechanisms simultaneously causing hard to treat infections. In 
addition, bacteria prefer to live in communities, attach to surfaces and embed 
themselves in a self-produced matrix.15 This lifestyle is known as biofilm and 
it offers the bacteria many advantages. The matrix of the biofilm improves 
cellular communication and provides a mechanical shield by acting as a 
permeability barrier to antibiotics, thus increasing resistance. Taken together, 
novel tools are needed to prevent and treat infections caused by resistant 
bacteria and disrupt the biofilm structure. 
1.3 INFECTIONS RELATED TO ANTIMICROBIAL 
RESISTANCE 
Antimicrobial resistance is becoming a global life threat.19 In particular, the 
so-called ESKAPE pathogens Enterococcus faecium, S. aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Enterobacter species and their resistant forms are of great concern.20 For 
example, a global pandemic of resistant S. aureus kills more Americans per 
year than HIV, emphysema, Parkinson’s disease and homicide combined.21 
The most serious bacterial infections happen in healthcare environments such 
as care homes and hospitals. The patients at greater risk of healthcare-
associated infections are immunocompromised and invasive surgery 
patients.22 Infections related to the use of medical devices pose an especially 
significant financial burden. Catheter-related urinary tract infections, lower 
respiratory tract infections and infections related to surgeries are the most 
common. 
In addition to being challenging to treat, antimicrobial resistance adds 
considerable costs to the healthcare systems.23 Patients with persistent 




second-line antibiotics are not effective anymore, doctors prescribe the so-
called antibiotics of last resort that are generally very expensive. A study by 
Thorpe and colleagues analysed data from the Medical Expenditure Panel 
Survey24 to estimate extra costs of treating resistant infections.25 They 
estimated an additional cost of USD 1,383 per patient due to resistant bacterial 
infection. Currently, the most notorious Gram-positive resistant bacterium is S. 
aureus.26 It is a spherical bacterium, which clusters in a grape-like form. It is 1 
μm in diameter and can exist asymptomatically on many parts of the human 
body including the mucous membrane and skin.27 
1.4 EXAMPLES OF ANTIMICROBIAL-RESISTANT 
BACTERIA 
1.4.1 MRSA 
Methicillin-resistant S. aureus (MRSA) is any strain of S. aureus that has 
developed resistance towards the broad-spectrum β-lactam antibiotics such 
as cloxacillin, methicillin and flucloxacillin.28 MRSA has developed resistance 
towards many antimicrobial agents including fluoroquinolones, 
aminoglycosides, cephalosporins, macrolides and β-lactams as well as 
vancomycin, trimethoprim-sulfamethoxazole and tetracycline.29 In the USA, 
19,000 people die every year due to MRSA.30 
The emergence of resistant S. aureus species developed in a series of 
steps. In the 1940s, the number of infections related to penicillin-resistant S. 
aureus increased in healthcare sectors.29 This strain was able to develop 
penicillinase, which hydrolyzes the strained β-lactam ring of penicillin. The 
next step followed when methicillin was introduced in the 1960s. This time the 
mechanism of resistance differed from the penicillinase-mediated resistance. 
It was much broader and included resistance to all β-lactam class antibiotics, 
such as carbapenems, cephalosporins and penicillin. By the mid-1980s the 
MRSA pandemic started in hospitals and healthcare centers, resulting in the 
increased use of vancomycin. Vancomycin was the last remaining antibiotic to 
which MRSA was susceptible. The intensive use of vancomycin resulted in the 
emergence of vancomycin-intermediate S. aureus (VISA). 
Currently, MRSA is one of the fastest evolving bacteria, causing a wide 
range of infections from skin disease to serious endocarditis.31 Various 
sequelae can result from MRSA infection such as chronic wound infection, 
septic conditions, bloodstream infection and ventilator-associated 
pneumonia.32 MRSA is the leading cause of chronic infections for indwelling 
medical devices.33 
MRSA can asymptomatically colonize in its host (almost 30% of humans 
are carriers), where it transmits easily through skin contact.29 MRSA infection 
is divided into two categories based on the genetic makeup: hospital-acquired 
infection and community-acquired infection (HA-MRSA and CA-MRSA, 
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respectively).30 In the community setting, MRSA causes skin and lung 
infections, which can become severe if left untreated.34 However, in healthcare 
settings, MRSA causes more serious infections. Bloodstream and surgical site 
infections and pneumonia are the most common. The infection risk increases 
in crowded places, especially with frequent skin contact or through the sharing 
of personal items. 
HA-MRSA is a vigorous MRSA type that infects hospitalized 
immunocompromised patients.35 Lopes and colleagues did a cross-sectional 
study, where they tested the saliva and nasal secretion of 100 nurses providing 
care for immunocompromised HIV patients.36 They detected S. aureus in 43% 
of the tested subjects. A bacterial resistance study showed that 92% of S. 
aureus was resistant to penicillin, 45% to erythromycin, 42% to clindamycin 
and 15% to oxacillin. 
The biggest challenge in treating HA-MRSA is its ability to grow within 
biofilms that protect them against different therapies. 
Bacteria can exist in three different states.37 The first state is the planktonic 
single-cell state that causes acute infections. Antimicrobial agents can easily 
eradicate planktonic cells. In the second state, bacteria form communities in a 
self-produced matrix and this bacterial lifestyle is called biofilm that causes 
hard-to-treat infections. The treatment of biofilms remains ineffective with 
conventional antimicrobial agents. The third state is dispersed and 
corresponds to a stage between planktonic and biofilm states. This state 
facilitates biofilm spreading and the transmission of infection. 
1.4.2 BIOFILM 
Biofilms are communities of microorganisms that attach to each other and 
to living or non-living surfaces.38 The adherent cells live in a self-produced 
slimy extracellular polymeric matrix. This lifestyle allows the microorganisms 
to share nutrients and survive physicochemical aggression such as 
desiccation, acidity, heavy metals, salinity, phagocytosis and antibiotics.10 
Biofilm formation involves several phases (Figure 2).39,40 The first phase 
requires cells to attach reversibly onto a surface. Cells adhere initially through 
hydrophobic interactions or van der Waals forces.41,42 In favorable conditions, 
bacteria anchor themselves irreversibly to the surface using attachment cells 
such as pili and produce biofilm matrix components forming microcolonies. 
The extracellular matrix (ECM) protects the biofilm from stress conditions, and 
it contains a mixture of lipids, proteins, nucleic acids and polysaccharides.37 
The matrix secretion continues until the third stage of the biofilm, where it 






Figure 2 Demonstration of S. aureus biofilm formation. Biofilm formation starts with initial 
 attachment, which develops into irreversible attachment, ECM generation and 
 microcolony formation. Bacteria multiply and biofilm becomes mature after which cells 
 disperse to a new surface to form a new biofilm (adapted from Lu et al. 2019).39 
During colonization, bacterial cells communicate through a system known 
as quorum sensing (QS). During this process bacteria share information using 
small signaling molecules, which allow them to grow and mature into large 
cellular aggregates. Studies have shown that the QS systems are different 
between Gram-negative and Gram-positive bacteria.43 Gram-negative 
bacteria use mainly N-acylated homoserine lactone (HSL) molecules for 
communication (Figure 3) while Gram-positive bacteria use modified 
oligopeptides. The mature biofilm forms water channels to efflux waste and 
influx nutrients. In the final stage, the mature bacteria disperse to new niches 




Figure 3  Examples of the most common class of signalling molecules produced by Gram-
 negative bacteria. They have N-acylated homoserine lactone ring and different 
 length carbon acyl chain (adapted from Papenfort and Bassler 2016).44 
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Biofilm cells are physiologically different from planktonic cells of the same 
bacterial species.45 Planktonic cells switch to biofilm mode after a phenotypic 
shift in behavior and gene regulation.46 Typically, biofilms are formed in 
response to different factors such as recognition of an attachment site, 
exposure to sub-inhibitory doses of antimicrobial agents or nutritional 
cues.45,47 It is estimated that over 80% of human bacterial infections are 
biofilm-related.48 
In most cases, antimicrobial agents reduce biofilm mass but do not 
eliminate the entire biofilm. A subpopulation of bacterial cells (less than 1%) 
known as “persister cells” enter a dormant state to escape the effect of 
antimicrobials without genetic modification.10 After the end of antibiotic 
exposure, persister cells resume growing to form a new biofilm. As persister 
cells survive antibiotics, they can cause infection recurrence even after the 
administration of high concentrations of antibiotics for a long time. Thus, the 
reason of biofilm resistance toward antibiotics relies mainly on the presence 
of such persister cells. Studies of dose-dependent killing of P. aeruginosa 
biofilm have shown the presence of persister cells as a small subpopulation of 
bacterial cells completely tolerant to antibiotics such as ciprofloxacin and 
ofloxacin.49 
Examples of persistent infections comprise of endocarditis caused by 
staphylococcal biofilms and medical device-associated infections, such as P. 
aeruginosa lung infections and streptococcal otitis media. These infections 
can be cured or alleviated partially but require prolonged treatment periods.22 
Moreover, the biofilm structure protects the bacteria against the immune 
system as it impairs the activation of phagocytes and complement systems 
causing a 1000-fold resistance towards conventional antibiotics.37 Studies 
have shown that biofilm cells undergo a higher rate of mutation compared to 
planktonic cells. That results in a 10-fold increase in the ability of the bacteria 





2 REVIEW OF THE LITERATURE 
2.1 ANTIMICROBIAL AND ANTI-BIOFILM AGENTS 
The common way of treating antibiotic-resistant biofilm infections is through 
the administration of higher doses of antimicrobial agents or by using 
alternative antimicrobial agents as such or in combination with other agents. 
Ideally, they should penetrate the biofilm matrix and be effective towards the 
bacterial species forming the biofilm.37 The use of antimicrobial agent 
combinations is preferred as different mechanisms of actions strengthen the 
overall effect of treatment. Antimicrobial agents are divided into various 
categories depending on their modes of action. They can inhibit the formation 
of the polymer matrix, suppress the adhesion of bacterial cells onto surfaces 
or decrease the production of virulence factors by disturbing the QS network.43 
They can also interfere with the synthesis of deoxyribonucleic acid (DNA) and 
ribonucleic acid (RNA) or interfere with the bacterial cell wall formation. Other 
modes of action include lysis of the bacterial membrane, inhibition of the 
bacterial metabolic pathways and protein synthesis.11 
2.1.1 THE ANTIMICROBIAL ACTIVITIES OF RESIN TERPENOIDS WITH 
FOCUS ON DEHYDROABIETIC ACID 
Conifers are one of the oldest plant species found on Earth with the earliest 
fossil dating back to 300 million years ago.51 Conifers have a highly evolved 
defence system, which protects them from outer invaders. When wounded, 
the trees secret viscous oleoresin, which traps the invading insects and seals 
the tree wound.52 Resin consists mainly of volatile and non-volatile terpenes. 
Terpenes have a cycloaliphatic structure made of isoprene units assembled to 
each other in various ways. The common terpenes are classified mainly based 
on their carbon units as monoterpenes (C10), sesquiterpenes (C15), diterpenes 
(C20), sesterpenes (C25) and triterpenes (C30).53 When terpenes are modified 
by removing methyl groups or adding oxygen atoms, they are referred to as 
terpenoids. Under natural conditions, volatile terpenes evaporate from resin, 
leaving behind a solid portion of non-volatile components, comprising 
diterpenoids, known as rosin. 
Studies have shown that terpenes and terpenoids possess antibacterial 
and antifungal activities.54,55,56 Fallarero et al. screened a library of natural and 
semi-synthetic abietane-type diterpenoids against S. aureus biofilms.57 The 
most active compounds were nordehydroabietylamine (7), (+)-
dehydroabietylamine (DHAA) (8) and (+)-dehydroabietic acid (DAA) (9) 
(Figure 4). They prevented biofilm formation (in the pre-exposure assay) and 
disrupted pre-formed biofilms (in the post-exposure assay) in the micromolar 
range. DAA had the highest selectivity towards the tested biofilms. Non-
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specific cytotoxicity studies on three mammalian cell lines revealed that DAA 
was well tolerated. 
 
 
Figure 4 Structures of nordehydroabietylamine (7), DHAA (8) and DAA (9) studied against S. 
 aureus biofilms in the pre- and post-exposure assays. 
Different studies have focused on the modifications of diterpenoids to 
improve their bioactivities.58 So far, DAA is the most extensively studied. 
To enhance the biofilm potency of DAA, Manner and colleagues modified 
rings A and B of its diterpenoid core and combined it with different amino 
acids.56 They screened the compounds against the biofilms of two different S. 
aureus strains in pre- and post-exposure assays. The initial screening was 
done at 400 μM and the active hits were retested at 100 μM concentration. 
The group identified the best potent anti-biofilm compound 11 (Figure 5) with 
minimum inhibitory concentration (MIC) values of 15 μM and 20 μM for S. 
aureus ATCC 25923 and Newman, respectively. Mechanism-of-action studies 
revealed that the compound 11 likely targets the bacterial cell membrane and 
disrupts the formed biofilm. The compound showed no statistically significant 
reduction in HL cells (originating from the human respiratory tract) when tested 
up to 100 μM proving to be non-cytotoxic to human cells at the concentrations 








In a mission to target different strains of MRSA and methicillin-susceptible 
S. aureus (MSSA), Chabán and colleagues developed a new series of 
abietatrienes from DAA by modifying the C13 position of ring C.59 The library 
of 29 compounds was tested against the following bacterial strains: MRSA 
ATCC 33592, LA-MRSA LGA251(ST425-XI), HA-MRSA ST5-SCCmecI, 
MSSA ATCC 6538 and ST30-t021. The research group used three antibiotics, 
gentamicin, vancomycin and penicillin as reference substances. Based on the 
displayed activity, four compounds (Figure 6) were chosen for further testing 
against 12 MRSA and 9 MSSA strains. Compound 13 showed potent 
antibacterial activity with low MIC values against all the tested strains followed 
by compound 12. Compound 15 was active against all but one strain, while 14 
was active against 6 MRSA strains. Compound 13 was tested against human 
erythrocytes at 181 μM, a value much higher than its MIC, and showed no 
cytotoxicity. The group concluded that an oxime moiety at C13 combined with 
a free hydroxyl group at C12 enhances the activity of DAA towards different 
S. aureus strains. 
 
 
Figure 6 The structure of the most active DAA derivatives synthesized by Chabán et al. 2019 
 and their antibacterial activities. 
Liu et al. synthesized a series of 12-oxime and O-oxime ether derivatives 
of DAA by modifying the C12 substituent and tested them for their anti-
staphylococcal activity.60 The compounds were tested against S. aureus and 
five multidrug-resistant strains (NRS-1, NRS-70, NRS-100, NRS-108, and 
NRS-271). The aromatic oximate 18 (Table 1) was the most active against S. 
aureus Newman with low MIC values ranging between 0.8 and 1.6 μM. In 
comparison, the parent compound DAA had moderate activity against 
Newman strain with MIC values ranging between 41 and 66 μM. The three 
compounds 16, 17 and 19 were the most potent against the five multidrug-
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resistant S. aureus strains. The research group concluded that the presence 
of an oxime functionality at C12 enhanced the activity of DAA against 




Table 1 Structure of DAA oximate derivatives, their MIC values against S. aureus Newman 
 strain and their MIC ranges against all the tested bacterial strains. 
Compound 
 













H 3.2-6.4 3.2-6.4 
    18 
 
CH3 0.8-1.6 0.8-24.9 
19 
 
H 3.2-6.4 3.2-6.4 
 
In another study, derivatives of DAA were synthesized and their activities 
were tested against a filamentous fungus, yeasts, and bacteria (Figure 7).61 
Modifications were done using different configurations on the asymmetric 
carbon atoms of the A/B ring junction and different functional groups at C18, 
C7 or C12, without an isopropyl group at C13. All compounds showed activity 
against the fungus Trichophyton mentagrophytes. Compounds 20 and 23 
showed significant relative inhibition (RI) of 100% while compounds 25 and 29 
showed RI of 91% and 90%, respectively. The absence of the isopropyl group 
at C13 and the presence of hydroxyl groups at C7 or C12 enhanced the 
activity. The stereochemical differences were not significant for the activity as 







Figure 7 The structure of DAA derivatives synthesized by Gigante et al. 2002. 
Only compounds with a formyl group at C18 showed activity against 
several Candida strains. Compound 30 exhibited significant antifungal activity 
with MIC values 26.9-53.8 μM. The activity was improved more than two-fold 
with a ketone carbonyl present at C7 as 33 had MIC values 12.7-25.4 μM. 
None of the compounds were active against the Gram-negative bacteria P. 
aeruginosa and Serratia marcescens. Compounds containing hydroxyl or 
formyl groups at C4 such as 21, 22, 25, 29 and 30 showed good activity 
against S. aureus with MIC values of 5.6, 5.6, 6.5, 6.5 and 6.6 μM, 
respectively. The parent compound DAA was not active below a 40 μM 
concentration when tested against S. aureus. The different stereochemistry 
and the presence or absence of the isopropyl group at C13 did not affect the 
activity. It was concluded that a simple derivatization of DAA had a significant 
impact on the antimicrobial activity of its derivatives. 
2.1.2 THE ANTIMICROBIAL ACTIVITIES OF PYRIMIDINES 
Pyrimidines are six-membered aromatic heterocyclic compounds with two 
nitrogen atoms at 1,3-positions of the ring.62 Substituted pyrimidines have 
essential functions in all living organisms and human metabolism. They are 
constituents of human RNA and DNA. 
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Different pyrimidine-based compounds show remarkable antimicrobial 
activities (Figure 8). Trimethoprim (TMP) is a marketed trisubstituted 
pyrimidine-containing drug, which binds to dihydrofolate reductase and inhibits 
the conversion of dihydrofolic acid (DHF) to tetrahydrofolic acid (THF), 
inhibiting bacterial DNA synthesis.63 It is used to treat acute urinary tract 
infection.64 Recently, different analogues of trimethoprim have been 
developed in the search for new antibiotics with better pharmacological 
profiles. Brodimoprim is another trimethoprim analogue with a similar 
antibacterial spectrum to its parent compound.65 It is also a selective inhibitor 
of bacterial dihydrofolate reductase (DHFR) but has a longer half-life 
compared to trimethoprim. 
 
 
Figure 8 Pyrimidine core and antibacterial trisubstituted and tetrasubstituted pyrimidines. 
Iclaprim is a trisubstituted pyrimidine and an optimized trimethoprim 
analogue.66 Like its parent compound, iclaprim selectively inhibits the 
synthesis of dihydrofolate reductase, essential for the synthesis of bacterial 
RNA, DNA and proteins. It was mainly developed to gain activity against TMP-
resistant strains and other resistant bacteria.67 Iclaprim has reached phase III 
clinical trials for the treatment of acute skin infections and Gram-positive 
hospital-acquired pneumonia. A study evaluated the activity of iclaprim against 
MRSA in an in vitro pilot study.66 The study was conducted using 61 different 
MRSA isolates, which were not susceptible to different antimicrobial agents 
including vancomycin, daptomycin and linezolid. As demonstrated in Table 2, 
iclaprim exhibited potent activity in the micromolar range against all the 
isolates. Furthermore, the bactericidal activity of iclaprim was studied using a 
time-kill assay, which showed that the molecule is fast-acting. It exhibited 
bactericidal activity against the different MRSA phenotypes at 4-8 h. The 
research team concluded that iclaprim is highly active and rapidly acting. 
However, the iclaprim marketing approval application was withdrawn from the 




drug was as good as comparator antimicrobial agents. Furthermore, 
resistance has already been developed before it is in general use. 
 
Table 2 The antimicrobial activity of iclaprim against different MRSA isolates. 
MRSA phenotype MIC range (μM) 
Daptomycin non-susceptible (n=7) 0.34-22.57 
Linezolid non-susceptible (n = 26) 0.08-2.82 
Vancomycin intermediate (n = 23) 0.71-22.57 
Vancomycin resistant (n = 5) 0.71-22.57 
 
As demonstrated above, the most common and fastest strategy for 
developing new antimicrobial agents is mainly through modifying the existing 
analogues.69 However, the new analogues tend to have the same 
macromolecular target and similar structure to that of the parent compound. 
The absence of structural variation often leads to accelerated antimicrobial 
resistance. Taken together, current studies focus on designing and 
synthesizing novel pyrimidine derivatives to target resistant bacteria. 
Veeraswamy and colleagues synthesized a library of novel pyrido[2,3-
d]pyrimidines and screened them for their antibacterial activity against seven 
different Gram-positive and Gram-negative bacteria.70 Compounds 40, 41, 45 
were active against all tested bacteria (Table 3). Compound 42 was active 
against the Gram-positive S. aureus and the Gram-negative Klebsiella 
planticola with MIC values 16.5 and 32.9 μM, respectively. Compound 43 
exhibited specific activity towards S. aureus only with MIC value 15.4 μM. 
Compounds 39 and 44 had specific activity towards K. planticola. The rest of 
















Table 3 The chemical structures of the most active pyrido[2,3-d]pyrimidines and their 
antimicrobial activities. 
Compound R1 R2 MIC (μM) 




















The Sec pathway is the major route responsible for secreting protein across 
the bacterial cytoplasmic membrane.71 A key component of this pathway is 
ATPase SecA, which mediates protein translocation. Jang et al. synthesized 
a novel series of thiazolo[4,5-d]pyrimidines and assessed their ability to inhibit 
the intrinsic SecA ATPase activity of S. aureus and E. coli. The compounds 
were tested at 200 μM. The most active compounds were 46 and 47, as they 
inhibited the intrinsic E. coli SecA ATPase activity by 76% and 70%, 
respectively (Figure 9). The IC50 values of 46 and 47 were found to be 135 μM 








Figure 9 The chemical structures of the most active compounds 46 and 47. 
In another study, a series of 6-substituted 4-aminopyrazolo[3,4-
d]pyrimidines were prepared and screened against four Gram-positive and 
three Gram-negative bacteria (Table 4).72 Most of the tested compounds 
exhibited significant activities toward the Gram-positive Streptococcus 
pyogenes and the Gram-negative P. aeruginosa. The activity of the 
compounds was ranked 48 > 53 > 50 > 51 > 52 > 54 > 49. Compound 48 had 
broad-spectrum activity and was the most active with MIC values ranging 
between 0.1 and 17.1. The aliphatic methyl substituent showed the most 
activity followed by the monosubstituted phenyl and the disubstituted phenyl, 
respectively. Among 49-54, the 4-chlorophenyl substituted 53 was the most 
active while the presence of residual chlorine substituent in 54 decreased the 
activity. 
 
Table 4 The chemical structure and the MIC values of 48-54 against the most relevant bacterial 
strains, Streptococcus pyogenes and P. aeruginosa in mM. 




48 CH3 0.3 2.1 
49 C6H5 N.A.a 1.7 
50 4-CH3-C6H4 1.6 1.6 
51 4-Br-C6H4 0.1 1.4 
52 4-NO2-C6H4 0.7 1.5 
53 4-Cl-C6H4 1.5 3.1 
54 2,4-di-Cl-C6H3 1.38 2.8 




In a recent study, Bai et al. synthesized a library of novel pyrimidine 
derivatives and screened them for their antibacterial activities against S. 
aureus, Streptococcus mutans, E. coli and the fungus C. albicans.73 
Compounds 55, 57, 58, 59 and 60 had good activity towards the tested 
microbes (Figure 10). Compound 56 was identified as the most active one. It 
was apparent that the position of the 2,4-dichlorobenzyloxy group with respect 
to the benzene ring affected the activity as 56 was more active than 57. In 
addition to that, the position of the 2,4-dichloro substituent on the benzyloxy 
substituent influenced the activity, as 56 was more active than 55. Molecular 
docking simulation revealed that 56 interacts well with the active cavities of 
dihydrofolate reductase, an essential enzyme in the folate synthesis pathway. 
The cytotoxicity evaluation of 56 and 57 in human liver cells proved that they 




Figure 10 The chemical structures and MIC values of the most active pyrimidine derivatives 
against S. aureus, S. mutans, and E. coli as well as antifungal activities (C. albicans). 
As antimicrobial resistance continues to rise, new antibiotics and other 
antimicrobial agent classes and innovative treatment approaches of infectious 
bacterial diseases are needed. Some pyrimidine derivatives have successfully 
reached the market and have proven to be effective and safe. A variety of 
studies yielded new promising scaffolds with potent broad-spectrum 
antimicrobial activities. This highlights the value of pyrimidines as promising 




2.2 DESIGN PRINCIPLE OF ANTIMICROBIAL 
SURFACES 
Contamination of surfaces with resistant bacteria represents a great 
challenge. Bacteria prefer to colonize an existing surface rather than dwell in 
the planktonic state.74 Bacteria attach to surfaces to enhance membrane 
stability and reduce the net negative charge of the cells.75 Surfaces also help 
protect the cells against environmental threats.76 Bacteria can colonize 
different materials including fluorinated materials, glass, stainless steel, 
aluminum and different organic polymers. They can also attach onto surfaces 
that should resist attachment by depositing a layer of protein, which masks the 
functional groups that could reduce cell attachment. Bacterial colonization 
causes transmission of infection from surface to surface and to humans.77 This 
is problematic in a wide range of areas as it reduces the operational function 
of surfaces and devices. Examples of affected surfaces include petroleum 
pipelines, textiles, medical implants and aquatic flow systems.78,79 For 
example, the attachment of bacteria onto biomedical and indwelling devices 
and surgical implants introduces pathogenic bacteria into the human body.80 
Many physical and chemical factors are known to affect bacterial 
attachment onto surfaces. Examples include hydrophobicity, surface charge, 
chemical environment and surface topography (Figure 11). van der Waals 
forces and interfacial electrostatic interactions clearly influence the interaction 
between bacterial cell walls and surfaces. 
 
 
Figure 11 Factors guiding the initial attachment of bacteria to a surface. The initial 
 attachment is governed by van der Waals interactions to overcome energy 
 barriers. After overcoming this obstacle, hydrophobic-hydrophobic interactions 
 occur between the bacteria and the substrate. At this stage, bacterial curli, 
 fimbriae, flagella, and pili interact with the surface. Hydrophobic cells attach 
 strongly to hydrophobic surfaces. Substrate surface topography physically 
 influences bacterial adhesion (adapted from Renner and Weibel 2011).80 
Charged chemically modified surfaces act by direct contact between the 
antibacterial agents and the bacterial cell wall.81,82 The head groups of 
phospholipids in the bacterial cellular membranes are negatively charged. 
Surfaces containing quaternary ammonium groups or primary to tertiary 
ammonium cations contain a positively charged nitrogen atom. This interacts 
with the negatively charged cell membrane causing a disturbance in the lipid 
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bilayers and a subsequent leakage in potassium ions.83 As a result, bacterial 
cells lose their physiological functions and die. 
Therefore, positively charged surfaces attract bacteria and negatively 
charged ones should repel them. However, attraction forces such as 
hydrophobic interactions (e.g., low surface energy) and van der Waals forces 
can overcome the electrostatic repulsion between bacteria and anionic 
surfaces.80,84 Destabilizing interactions between negatively charged surfaces 
and bacterial cells can also be overcome by bacterial extracellular organelles 
including flagella, fimbriae curli, and pili, as they promote adhesion. 80,85 
Antibacterial surfaces have been categorized in the literature based on 
their mechanism of action.86 There are three main approaches to design 
antimicrobial surfaces.87 The first strategy focuses on preventing the initial 
attachment of bacteria by a so-called anti-biofouling or anti-adhesion effect. 
This is achieved by modifying the physicochemical properties of the surface 
such as hydrophobicity, topography, surface energy and roughness (Figure 
12). 
The second approach focuses on designing leaching surfaces that release 
antibacterial agents or inorganic metal ions from the surface over a period.87 
This approach has some disadvantages, because the residual amounts of 
antimicrobial leftover to the surrounding may cause adverse human health and 
environmental effects.88,89 Also, these surfaces have a limited life span due to 
the gradual release of the antimicrobial agents. 
The third approach aims to overcome these problems by covalently 
immobilizing antibacterial agents onto surfaces to kill bacteria upon contact. 
The covalent linkage forms stable and reliable antimicrobial surfaces without 




Figure 12 Examples of approaches used to design antibacterial surfaces. Antibiofouling surfaces 
 repel bacterial cells from attaching by creating unfavorable conditions. Bactericidal 
 surfaces kill bacterial cells upon contact. 
Biodegradable polymeric materials have great potential in advancing 
biomedical applications.90 While designing biodegradable biomaterials, 
different properties are considered, including biocompatibility, degradability, 




Different polymers of synthetic or natural origin have been used for 
biomedical applications. Examples of the most widely used synthetic polymers 
include polyphosphazenes, polyacetals, polyphosphoesters, polyanhydrides, 
polycaprolactone and poly(orthoesters).90 Even though these polymers fit 
functional demand, most of them are complex to synthesize, possess weak 
mechanical properties or have limited degradation. 
Plant- and animal-based natural polymers, such as hyaluronic acid, 
chondroitin sulfate, cellulose, chitin and chitosan are widely used in biomedical 
applications.91 In general, natural polymers are biocompatible, have excellent 
biodegradability, are cost-effective and easy to obtain in large amounts.92 
Recently, cellulose has been emerging as a promising natural and renewable 
polymer for biomedical applications.93 This is due to its low cost, excellent 
mechanical properties, biodegradability, biocompatibility and low toxicity. 
2.2.1 CELLULOSE NANOFIBERS 
Cellulose 61 is a renewable raw material with a wide capacity for chemical 
modifications.94 It is the most abundant polymer on earth with an annual 
production of 1.5×1012 tons produced from wood pulp and cotton. Cellulose is 
composed of repeating D-glucose units linked together by β-1,4 linkages with 
the formula (C6H10O5)n where n is the degree of polymerization (Figure 13). 
Cellulose is 44.4% carbon, 49.4% oxygen and 6.2% hydrogen.95 Cellulose has 
crystalline and amorphous regions in its structure with accessible hydroxyl 
groups on its surface.96 Thus, cellulose is hydrophilic, and it swells in water. 
As cellulose is non-toxic and widely available, it has been used for a wide 
range of applications. Recently, the interest in the hydrophobization of 
cellulose has increased as a mean to explore its use in new applications.97 
Hydrophobicity of cellulose is measured by depositing a water droplet on its 
surface and assessing its contact angle (CA). In general, a material is 
considered hydrophobic when the CA is higher than 90°.98 
 
Figure 13 The chemical structure of cellulose (adapted from Klemm et al. 2005).94 
Cellulose nanofibrils (CNF) are prepared mechanically via high shearing of 
cellulose fibers to achieve length in micrometric range and width in the 
nanometric range.99 After shearing, the mass is homogenized at high 
pressure. This process provides entangled cellulose nanofibers with 
alternating amorphous and crystalline regions. 
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The nanoscale provides the CNF with an expanded uniform surface area 
where the hydroxyl groups on its structure can be chemically modified to 
create value-added advanced materials. Robust and solvent-resistant thin 
films can be made of CNF with excellent barrier properties to grease and 
atmospheric oxygen.100 Those films represent a great platform for chemical 
modification to create functional materials. Different studies have focused on 
preparing nanocellulose with antimicrobial properties.101,102,103,104 The most 
common methods to design non-leaching antibacterial nanocellulose surfaces 
have focused on hydroxyl substitution or other covalent surface modification 
reactions.105 Esterification and silanation are commonly used modification 
methods. Various compounds have been used to esterify cellulose to produce 
high-performance active materials with antimicrobial properties. 
Saini and colleagues modified the surface of nanocellulose with the β-
lactam antibiotic benzylpenicillin (Figure 13).106 The hydroxyl groups of the 
nanocellulose were reacted with the carboxyl group of the thiazolidine ring of 
benzylpenicillin. The esterification rendered relatively hydrophobic films with 
CA 89  ± 10°. The modified films were assessed for their antimicrobial activity 
against S. aureus and E. coli after a 24-h incubation. The modified 
nanocellulose exhibited strong activity against S. aureus as it reduced the 
number of viable staphylococci by 3.5 log units. However, benzylpenicillin-
grafted nanocellulose was not active against E. coli. The research group 
speculated that this may be because penicillin acts on the bacterial cell wall. 
Gram-negative E. coli has an outer layer of lipopolysaccharide (LPS) that 
prevents the access of penicillin to the cell wall. 
 
 
Figure 14 Benzylpenicillin-grafted nanocellulose. 
Surface functionalization of cellulose nanocrystals (CNC) with resin acids 
provides the cellulose with hydrophobic and antimicrobial properties. de 
Castro and colleagues esterified the surface of CNC with rosin, a bio-based 
mixture of abietic and pimaric-type resin acids (Figure 15).107 The research 
group tested the antimicrobial activity of neat and rosin grafted CNCs on 
Gram negative E. coli and Gram positive Bacillus subtilis. The modified CNC 
exhibited good antibacterial activity against B. subtilis and weak activity 
against E. coli, indicating that the Gram-positive bacteria are more sensitive to 
rosin. The authors explained that modified CNC most likely reacts with the 




structure of the cell wall between Gram-positive and Gram-negative bacteria 
would explain the selectivity of modified CNC. 
 
 
Figure 15 The most representative diterpene resin acids of the coniferous rosin. 
In another study, Hassanpour et al. modified the surface of CNF with 
siloxane-linked phenanthridinium iodide and developed hydrophobic, non-
leaching antibacterial films with different degrees of substitution.87 First, the 
antibacterial agent (3-trimethoxysilylpropyl)phenanthridinium iodide (TMSPhI) 
was synthesized by reacting (3-chloropropyl)trimethoxysilane and 
phenanthridine in the presence of potassium iodide. Then the hydroxyl groups 
of CNF were reacted with the trimethoxysilyl group of TMSPhI to yield CNF-
TMSPhI (Figure 16). CA measurements showed that the modification 
rendered more hydrophobic films. 
Additionally, the research group tested the antibacterial properties of CNF-
TMSPhI films against S. aureus and E. coli. The antibacterial activity varied 
with respect to the amount of TMSPhI present on the surface. In general, the 
films exhibited strong bactericidal activities against E. coli, whereas S. aureus 
was less susceptible to CNF‒TMSPhI. The exact mechanism of action was 
not completely elucidated. However, the authors concluded that E. coli is more 
negatively charged than S. aureus and it reacts more efficiently with the 





Figure 16 Covalent grafting of TMSPhI on the surface of CNF. 
Currently, research on non-leaching antimicrobial nanocellulose is in the 
early stages and the number of studies dealing with this topic is low. Thus, 
further studies are needed to generate new classes of non-leaching 






3 AIMS OF THE STUDY 
This thesis has two aims. The first aim was to design and synthesize new 
nanocellulose-based antibacterial surfaces to limit bacterial spread and 
infection. The second aim was to reveal details of the antimicrobial and anti-
biofilm activity of pyrimidine derivatives and to establish their potential as a 
new class of hit compounds for discovery of novel drugs to treat infections 
caused by Gram-positive resistant bacteria. 
The research questions for the first aim can be summarized as following: 
Will the covalent linking of dehydroabietanes to CNF result in antimicrobial 
properties? Will the activity of the covalently bound compounds be like that of 
the unbound ones? How will the physical and chemical properties of CNF 
change after modification? The first hypotheses were that dehydroabietanes 
will gift CNF with antimicrobial properties and increase the hydrophobicity of 
the material. As the methods used to modify the CNF are gentle, the fibrous 
structure is supposed to keep its integrity. As the compounds will be bound to 
the CNF surface covalently, they will be locked in a specific orientation which 
can impact their antimicrobial activities. 
The research question for the second aim of the study was: Will chemical 
modification of the pyrimidine core render a potential new class of hit 
compounds with antibacterial properties? Studies have shown that modified 
pyrimidines possess a wide spectrum of biological activities, among which are 
antimicrobial activities. Thus, the second hypothesis was that chemical 
modification of pyrimidines will provide hit compounds that have antibacterial 
and anti-biofilm activities. 
3.1 OUTLINE 
The main findings of this research are displayed in the included articles, 
summarized as follows: 
 
● Publication I was devoted to the design and synthesis of novel non-
leaching contact-active surfaces using nanocellulose and 
dehydroabietylamine as a model compound due to its commercial 
availability. Pre-made CNF films were activated with carboxymethyl 
cellulose, after which the compounds were covalently linked to the 
surface through amide bond formation. The study yielded anionic 
surfaces that combine enhanced hydrophobicity with excellent broad-
spectrum antimicrobial activity, bearing low potential to spread 
resistance. The beneficial characteristics of the original CNF film such as 
mechanical strength, breathability and moisture buffering were retained. 
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● Publication II was a follow-up from the first study. Another class of 
contact-active surfaces was designed and synthesized using derivatives 
of naturally occurring dehydroabietic acid. Similarly, the study rendered 
anionic, biocompatible and non-leaching films with excellent antimicrobial 
properties. The antimicrobial activity was detailed further by including a 
model mimicking chronic wound conditions, showing that the films 
prevent biofilm formation and bacterial colonization. In addition, the films 
nurtured fibroblast growth at their surface, making them excellent 
platforms for biomedical applications. In this publication, we created the 
first fully sustainable and efficient antimicrobial CNF film, based on raw 
materials from nature. 
● Publication III focused on the design and synthesis of a new class of 
2,4,5,6-tetrasubstituted pyrimidines and the assessment of their 
antibacterial and anti-biofilm activities in vitro. We identified three active 
compounds that inhibited biofilm formation and disrupted already 
established biofilms of S. aureus with IC50 values ranging from 11.6 to 
62.0 μM. Mechanistic studies showed that the compounds do not act on 
the bacterial cell wall but instead they bind to intracellular bacterial 
targets. Cytotoxicity assessment showed moderate cytotoxicity against 





4 RESULTS AND DISCUSSION 
4.1 THE SYNTHESIS OF DEHYDROABIETYLAMINE-
BASED CNF 
Surfaces are highly sensitive to microbial attachment, causing infection 
spreading and contamination in health and industrial sectors.108 A common 
approach to develop antimicrobial surfaces is by developing biocide-releasing 
materials, which leach antimicrobials such as triclosan and silver to the 
environment. The spread of bioactive molecules to industrial goods is not 
desired in order to maintain product properties and limit resistance against 
bacteria.109 Currently, there is a growing interest in sustainable contact-kill 
surfaces. 
Cellulose is a fully renewable and biodegradable polymer with outstanding 
properties and mechanical strength. Getting cellulose microfibrils to the 
nanosized scale adds desired properties to the natural cellulose such as 
uniformity and large surface area.110 
Herein, we present the design and synthesis of innovative antimicrobial 
CNF films using (+)-dehydroabietylamine, a commercially available 
diterpenoid that was previously shown to possess antimicrobial activity.57,111 
This was done by covalently binding the diterpenoid and its derivative onto 
CNF films. Furthermore, we demonstrate the results of the material 
characterization and the antibacterial assessment. 
4.1.1 DESIGN AND SYNTHESIS 
Surface modification was done by chemically grafting 8 and its synthetic 
derivative 70 onto the CNF surface in a two-step reaction (Figure 18). First, 
the surface of CNF was enriched with carboxyl groups required to react with 
the amino groups of 8 or 70. The irreversible adsorption of sodium 
carboxymethyl cellulose (Na-CMC) onto CNF was done by stirring a 5-cm 
diameter circle of CNF in a 0.05 M/0.01 M solution of CaCl2/NaHCO3 in water 
containing Na-CMC, at 80 °C, for 4 h. 
Carboxymethyl cellulose (CMC) is a cellulose derivative, which possesses 
anionic carboxyl groups on its surface. A previous study has shown that CMC 
irreversibly adsorbed onto the negatively charged cellulose in the presence of 
electrolytes and increased its surface charge density (increased the negative 
charge of cellulose).112 In our reaction, the electrolytes help the CMC to 
approach the cellulose surface where irreversible adsorption happens guided 
by molecular/structural affinity.113 
We covalently linked the carboxyl groups on the CNF surface to 8 and 70 
to synthesize 72 and 73, respectively through the formation of an amide bond. 
To synthesize compound 70 (Figure 17), we reacted purified 8 with tert-butyl 
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(3-bromopropyl) carbamate and Cs2CO3 in DMF for 24 h. The reaction 
produced a mixture of mono- and bis-alkylated amines, which after 
chromatographic purification gave pure 69, in 14% yield. The tert-
butoxycarbonyl protecting group was removed after treating the compound 




Figure 17 The synthesis route of compound 70. 
 
 





4.1.2 SURFACE ANALYSIS AND CHARACTERIZATION 
The successful modification of CNF was shown by the subsequent CA 
measurements. CNF and 71 are hydrophilic polymers (Publication I). The 
amidation of CNF-CMC reduced the water wettability and increased the 
hydrophobicity of the films. There was an apparent increase in the CA of the 
modified material (above 70°) compared to unmodified CNF (CA 31.4° ± 0.8 ). 
This is expected as the covalently bound diterpenoids increased the carbon 
content at the CNF surface, suggesting a successful surface modification. 
An insight into the chemical composition of the surfaces was explored via 
X-ray photoelectron spectroscopy (XPS; Table 5). The elemental surface 
analysis was done with low resolution wide survey scans. For more details, 
high resolution scans were done. The C 1s and O 1s content of modified and 
unmodified CNF were measured from three different locations per sample. 
Nitrogen content was determined via regional N 1s scans. 
The XPS wide scan data of C 1s peak for unmodified and modified CNF is 
found from Figure 2 in Publication I. The main peaks corresponding to O and 
C are detected around 500 eV and 300 eV, respectively. The modified CNF 
showed new peaks at 400 eV corresponding to N atoms. Neither CMC nor 
cellulose has N in their chemical composition, thus, this change might have 
originated from our reaction. The surface O/C ratio for unmodified CNF is 0.74 
while for 72 and 73 are 0.58 and 0.67, respectively. The lower C-O content for 
the modified CNF indicates the presence of carbon-rich 8 or 70 on the surface. 
The high-resolution C 1s XPS spectra show that the intensity of C-C bond 
increases from 4.4% to 25% and 13.9% for unmodified CNF, 72 and 73, 
respectively (Table 5). The increase in aliphatic carbon denotes the success 
of the modification. 
 
Table 5 XPS data for 72 and 73. 
 Wide Scan Atomic Concentrations (%) High Resolution C 1s Carbon Fits 
Sample C 1s O 1s N 1s Si 2p C-C C-O O-C-O O-C=O 
CNF 60.7 39.3 0.0 0.0 4.4 74.5 19.2 1.9 
72 67.0 32.1 0.9 0.0 25.0 58.4 14.9 1.7 
73 62.2 35.9 1.3 0.7 13.9 66.5 17.2 2.5 
 
The surface coverage was calculated for 72 and 73 by dividing the 
measured N and C content with the theoretical one. Based on the N content, 
compound 8 covered 20% of the CNF film surface. However, when based on 
the C-C content, the compound covered 25% of the surface. We estimated the 
surface coverage of 73 to be 18% based on N and 14% based on C-C. Overall, 
our results indicate a very low surface coverage. 
We used atomic force microscopy (AFM) to investigate the nanoscale 
morphological details of unmodified and modified CNF. AFM height images 
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(Publication I, Table 3A) showed that the fibrous nanostructure of CNF 
remained unchanged after modification. 
The mechanical properties of CNF and the ability to permeate vapor were 
not significantly changed by the modification. As displayed in Table S1 in 
Publication I, the tensile strength of 72 did not differ from unmodified CNF. 
However, modified CNF had a higher oxygen permeability at a low relative 
humidity (50%) than the unmodified one. This can be explained by the 
increase in surface hydrophobicity, which attracts more oxygen molecules to 
the films. Overall, the results show that the surface modification done was 
gentle. 
To confirm that our changes occurred only on the surface, Fourier-
transform infrared spectra were recorded for CNF before and after grafting. 
The results are shown in Publication I (Figure 3B). Unmodified CNF showed 
characteristic bands of cellulose at 3334 cm−1, 2900 cm−1 and 1029 cm−1 for 
O-H, C-H and C-O-C, respectively. No significant differences were observed 
between modified and unmodified CNF indicating that the modification was 
done to the outermost surface. 
4.1.3 EVALUATION OF THE ANTIBACTERIAL ACTIVITY 
We investigated the ability of functionalized CNF to inhibit and kill different 
bacterial strains including Gram-positive S. aureus, Gram-negative E. coli, and 
methicillin-resistant S. aureus MRSA14TK301. Unmodified CNF was used as 
a control. As illustrated in Figure 19, the grafted materials exhibited 
remarkable activity against S. aureus. After 24 h of incubation, at 37 °C, a 
significant reduction of total cells from 105 colony-forming unit/mL (CFU/mL) 
bacterial suspensions was observed. Both 72 and 73 had obvious activity 
against MRSA with 91.3% and 98.4% reduction of total cells from the cell 
suspension, respectively. The film 72 succeeded in reducing total cells of E. 
coli from the bacterial suspension by 99.6% and 73 by 99.9%. 
 
Figure 19 Antimicrobial activity of 67, 71, 72, and 73 in percent reduction of CFU/mL of 105 
 bacterial suspensions. * not tested. 
We further investigated the effect of different solvents on the antimicrobial 
activity of 72 against S. aureus ATCC12598 (106 CFU/mL). After immersing 




except for treatments with dichloromethane (DCM) and 10% hydrochloric acid, 
72 was not altered and the antimicrobial activity was retained after the 
exposure to different solvents (Table S2, Publication I). These results suggest 
that 8 did not leach from the surface and that our surface chemistry is stable 
when treated with different solvents. 
As presented in the literature review, contact kill surfaces are created by 
binding biocides to them to gift them with contact-active antibacterial activity. 
To determine if 8 and 70 have the same antibacterial activities compared with 
their respective materials, we determined the minimal inhibitory concentration 
(MIC) values of 8 and 70 against S. aureus ATCC12598 and E. coli DH5α. In 
contrast to the materials, both compounds showed relatively weak 
antimicrobial activities (Table 6). Compound 8 had MIC values ranging 
between 40-50 μM while 70 had a slightly better MIC value of 30 μM. 
Incubation of 100 μM of 8 or 70 with the bacteria for 4 h showed bacterial cell 
death with ATP efflux indicating that the compounds caused disruption of the 
bacterial membrane. 
 
Table 6 The MIC values of 1 and 4 against S. aureus ATCC12598 and E. coli DH5α. 
MIC (μM) 
Compound S. aureus ATCC12598 E. coli DH5α 
8 40 50 
70 30 30 
 
The main reported factors that affect the activity of contact-kill surfaces are 
charge, hydrophobicity, topography and chemical surface composition. For 
example, cationic surfaces interact with the negatively charged bacterial cell 
wall and disrupt it.114 To understand better the interaction between bacteria 
and the material, we determined the surface charge of unmodified and 
modified CNF via stream current measurement (Figure 3C, Publication I). A 
background electrolyte of a 1 mM solution of KCl in water was used. The point 
of zero streaming was below pH 3 and reached an alkaline range, indicating 
that all the surfaces were negatively charged at the testing pH. As previously 
mentioned in the literature review, the electrostatic repulsion between the 
negatively charged surface of bacteria and anionic surfaces can be overcome 
by hydrophobic interactions and van der Waals forces. 
Next, the changes occurring in S. aureus bacterial membrane were 
investigated after incubation with the materials (24 h) or compounds (100 μM, 
1 h) using scanning electron microscope (SEM). As shown in Figure 4B 
(Publication I) no morphological changes were visible on the cells in contact 
with CNF and 72. Obvious debris appeared for cells in contact with 73 or 






Figure 20 S. aureus ATCC12598 under scanning electron microscope. A: untreated S. aureus; B: 
S. aureus incubated with neat CNF for 24 h; C: S. aureus incubated with 73 for 24 h.
4.1.4 BIOCOMPATIBILITY ASSESSMENT
Unspecific cytotoxicity is a common concern related to the development of 
antimicrobial materials, especially if they have the potential to be used in 
biomedical applications. The FDA biocompatibility guideline states that 
hemocompatibility testing, especially hemolysis testing, should be considered 
for agents which could have direct contact with circulating blood.115 We used 
hemolysis assay to determine if erythrocyte lysis is induced by contact with 
our surfaces. The film 72 showed a low level of hemolysis (0.9 ± 0.6) compared 
to that of the biocompatible116 CNF (0), while 73 showed a higher level of 
hemolysis (6.5 ± 1.9) as shown in Table 2 (Publication I).
We also used cell viability assay to determine the ability of cells to survive 
on our films. Human skin fibroblasts were incubated with the films for 72 h.
The cells colonized well on 72 to an extent comparable to unmodified CNF, 
which is considered biocompatible. However, only 3% of the cells colonized 
73, showing poor biocompatibility.
To our knowledge, this is the first study focusing on covalently linking 
antimicrobial diterpenes on CNF films via an amide bond. The success of the 
modification was confirmed by CA and XPS techniques. Even with low surface 
coverage, these antimicrobial surfaces proved to be very effective against 
Gram-positive and Gram-negative bacteria including the methicillin-resistant 
S. aureus MRSA14TK301 with good biocompatibility. Material 
characterization confirmed that the modified films retained the properties of 
the original CNF. Thus, diterpenes can be covalently bound to CNF to produce 
eco-friendly and inexpensive broad-spectrum antibacterial materials. The 
proposed mode of action together with the fact that the films are based on a





4.2 THE SYNTHESIS OF DEHYDROABIETIC ACID-
BASED CNF 
As previously reported, bacterial attachment and colonization cause 
biofilm-associated infections. S. aureus is found very frequently in biofilm-
associated infections.117 Diseases such as osteomyelitis, endocarditis, skin 
infections, urinary tract infection as well as implant associated infections are 
all caused by S. aureus biofilm infection. 
Dehydroabietic acid (DAA) is a diterpenoid found commonly in rosin.118 Our 
previous studies showed that linking different amino acids to DAA produced 
potent anti-biofilm compounds, which were more potent than conventional 
antibiotics.56 Inspired by these studies, we became interested in combining 
DAA derivatives with the biocompatible polymer CNF to extend structure-
property and investigate the modes of action of abietane-CNF hybrids. 
We designed and synthesized antimicrobial derivatives of DAA and 
covalently linked them to CNF films and further confirmed the success of the 
coupling reaction using time-of-flight secondary ion mass spectrometry (ToF-
SIMS) analysis. The films were screened for their antimicrobial activity against 
Gram-positive and Gram-negative bacteria including the methicillin-resistant 
S. aureus MRSA. Biocompatibility studies assessed the proliferation of human 
fibroblasts cells on their surface and hemolysis assay determined whether 
they induce red blood cell lysis upon contact. Also, an in vitro artificial dermis 
model was used to investigate the antibacterial activity of compounds and 
materials in wound-like conditions. 
4.2.1 DESIGN AND SYNTHESIS 
Compound 84 bears a methyl ester at C18 while 85 has a cyclohexyl-L-
alanine moiety in the same position. The compounds were synthesized by 
methylation of 9 or coupling with methyl ester hydrochloride of β-cyclohexyl-L-
alanine, respectively (Figure 21). The Friedel-Crafts acylation of the aromatic 
ring C of the compounds was done by reacting them with acetyl chloride and 
aluminium chloride in dichloromethane to give 76 in 89% yield and 77 in 56% 
yield. The Baeyer-Villiger oxidation of the acetyl-linked diterpenes was done 
by reacting them with peracetic acid (36-40 wt.%) in AcOH to yield 78 and 79. 
Conversion of 78 and 79 to 80 and 81, respectively, was done by letting the 
compounds react with K2CO3 in MeOH for 35 min. The hydroxyl groups of 
phenols were reacted with tert-butyl (3-bromopropyl) carbamate in the 





Figure 21 Synthesis of 84 and 85. Reagents and conditions: a. CH3I, K2CO3, DMF, r.t. for 74; b. 
 EDC HCl, DIPEA, HOBt, β-cyclohexyl-L-alanine methyl ester hydrochloride 
 DMF, r.t., 24 h for 75; c. AcCl, CH2Cl2, 0 °C to r.t.; d. AcOOH/AcOH, CH2Cl2, r.t; e. 
 K2CO3, MeOH, r.t.; f. tert-butyl (3-bromopropyl) carbamate, Cs2CO3, DMF, r.t.; g. TFA, 




Figure 22 Synthesis of 86 and 87. 
The compound tert-butyl (3-bromopropyl) carbamate was synthesized by 
reacting 3-bromopropylamine hydrobromide with di-tert-butyl dicarbonate in 
the presence of triethylamine in DCM. Finally, the amino groups of 82 and 83 
were deprotected by stirring the compounds with TFA in DCM to yield the final 
compounds 84 and 85 in 87% and 94% yields, respectively. The CNF films 
were activated by the irreversible adsorption of Na-CMC prior to linking 84 or 





4.2.2 SURFACE ANALYSIS AND CHARACTERIZATION 
We have previously shown that XPS is an excellent technique for the 
characterization of modified CNF films (Publication I). Tables 7 and 8 present 
the changes in the chemical composition of the CNF surface before and after 
modification. The main elements identified were carbon, oxygen and nitrogen. 
We detected nitrogen on the modified surfaces following the amide bond 
formation compared to unmodified CNF. These results suggest successfully 
completed surface modifications. The C-C content on the surface of modified 
films was significantly higher due to the presence of dehydroabietic acid 
derivatives on the surface. 
 
Table 7 Wide atomic scans (XPS) of neat and modified CNF films. 
Wide Scan Atomic Concentrations (%) 
Sample C 1s O 1s N 1s Si 2p 
CNF 60.7 39.3 0.0 0 
86 63.6 35.5 1.0 0 
87 62.8 35.3 1.2 0.5 
 
 
Table 8 High resolution C 1s carbon fits (XPS) for near and modified CNF. 
High Resolution C 1s Carbon Fits 
Sample C-C C-O O-C-O O-C=O 
CNF 4.4 74.5 19.2 1.9 
86 16.7 63.3 17.4 2.6 
87 13.0 66.2 17.9 2.7 
 
We calculated the surface coverage by dividing the measured C-C and N 
content with their corresponding theoretical values. The surface coverage for 
86 was estimated to be 20% and 14% for 87 based on the C-C content. When 
calculated based on the N content, it was 30% and 25% for 86 and 87, 
respectively. 
In line with low surface coverage values, FTIR analysis did not show any 
changes when comparing the modified films to neat CNF (Figure 23). This 
proved that only the outermost surface was modified. 
The CA measurements showed a more than two-fold increase in 
hydrophobicity of both 86 and 87 compared to neat CNF (Figure 24). The 
presence of 84 and 85 on the surface of CNF explains the increase in 




Figure 23 FTIR spectra of 67, 71, 87 and 86 showing no differences between them. 
 
 
Figure 24 Contact angle measurements at 5 and 30 seconds for 67, 86 and 87. 
 
To confirm the covalent coupling of 84 and 85 to CNF, we analyzed CNF, 
71, 85 and 87 using ToF-SIMS (Figures 3B and C, Publication II). This 
technique is commonly used to describe the chemical composition of solid 
surfaces. Compound 85 and 87 had a peak at m/z 541.5 in the positive ion 
mode. This peak was absent in CNF and CNF-CMC, indicating the presence 
of 85 on the surface of 87. Another peak appeared at m/z 696.7 (Figure 3A, 
Publication II) which might correspond to a CMC unit attached to a fragment 
of 87, where it is cleaved from the amide bond of ring A. This analysis confirms 
that our compounds are not adsorbed but covalently bound to the surface of 
CNF. 
The streaming current measurements for 71 and 87 at varying pH showed 
that the material was anionic under the condition of the bacterial assay. The 
point of zero streaming was in acidic pH and reached a plateau of alkaline pH 
(Figure 3D, Publication II). The negative charge can be explained by the 




As the surface coverage of 87 is low, a similar electrokinetic fingerprint can be 
observed between 71 and 87. 
4.2.3 EVALUATION OF THE ANTIBACTERIAL ACTIVITY 
The activity of the modified films was tested against different bacterial 
strains including Gram-negative E. coli, Gram-positive S. aureus and 
methicillin-resistant S. aureus MRSA14TK301. Log reduction describes the 
number of live microbes eliminated.119 One-log reduction translates to 10-fold 
or 90% reduction in the number of viable bacterial cells. The inclusion of 85 
on the CNF surface resulted in a significant 4-log reduction of staphylococcal 
cells in suspension (Figure 4B, Publication II). Moreover, 87 was active against 
viable MRSA and E. coli, with 5 and 2-log reduction in viable bacterial counts, 
respectively. The film 86 showed weaker antibacterial activity against the 
tested bacteria. 
In contrast to 87, compound 85 showed moderate antimicrobial activity 
against S. aureus with MIC value 15 μM and no activity against E. coli even 
when tested at 400 μM. Compound 84 showed weak activity against S. aureus 
and E. coli with MIC values 60 and 139 μM, respectively. These results clearly 
indicate that the mode of action of the films is different from that of the 
compounds. The incubation of 7 × MIC concentration of 85 with S. aureus for 
a short time did not cause apparent cell lysis which indicates that it is a slow-
acting compound (Figure 6A, Publication II). 
SEM images showed the morphological changes of S. aureus after 
incubation with CNF, 85 or 87 for 24 h (Figure 7, Publication II). Bacterial cells 
appeared unharmed with smooth, uniform and clear edges when in contact 
with unmodified CNF. However, collapsed cells were observed for round S. 
aureus when in contact with 85 or 87, which could be indicative of membrane 
lysis or poration. 
We investigated the ability of 87 to resist bacterial colonization in the 
artificial dermis and biofilm models. In the biofilm model, after 24 h of UAMS-
1 biofilm formation, a significant 2.5-log reduction in recovered CFU was 
observed for 87 when compared to the neat CNF (Figure 5A, Publication II). 
Furthermore, 87 was placed on top of an infected artificial dermis model that 
mimics chronic wound conditions. The dermis was infected with 1×104 CFU of 
S. aureus UAMS-1. After 24 h incubation, the modified CNF exhibited a clear 
1.4-log unit reduction in recovered CFU compared to unmodified CNF (Figure 
5C, Publication II). 
4.2.4 BIOCOMPATIBILITY ASSESSMENT 
Due to its remarkable activity, we selected 87 for further studies. As it 
showed robust antibacterial activity, its cytotoxicity against mammalian cells 
was evaluated (Figure 4C, Publication II). The film 87 showed a low hemolytic 
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rate (1.8%) when incubated with human erythrocytes for 1 h at 37 °C. 
Furthermore, the fibroblasts proliferate better on 87 than on the biocompatible 
CNF after 72 h incubation at 37 °C. 
4.2.5 STUDIES OF THE MECHANISTIC ACTION 
To gain a deeper insight into the mechanism of action of 87, we tested it 
against a mutant strain of Gram-positive Lactococcus lactis (LAC471) devoid 
of the AcmA autolysin. Autolysins are lytic enzymes at the surface of the 
bacteria responsible for cell wall turnover. The film 87 was only 10-fold less 
active against the mutated strain than against the original one. These results 
show that the release of autolysin is likely not the sole mechanism of action. 
The anionic charge of 87 can also bind to specific positively charged proteins 
on bacterial cell walls such as cationic autolysins.120 However, the existence 
of the β-cyclohexyl-L-alanine side chain had a great impact on the activity of 
87 compared to that of 86. Thus, the spatial orientation of 85 on the surface of 
CNF impacted the reaction of the surface with the bacteria. 
Our study generated anionic non-leaching surfaces with broad-spectrum 
antimicrobial activity. Upon contact, the films reduced MRSA-viable cells by 4-
5 log units, proving to be very efficient. Also, the films prevented bacterial 
colonization when tested in chronic wound like-conditions. Biocompatibility 
studies showed that fibroblasts proliferate on the surface of the films and very 
low level of hemolysis was observed. Our results highlight the value of CNF 
and dehydroabietic hybrid for biomedical applications. 
4.2.6 POTENTIAL MODE OF ACTION 
A close inspection of the modified CNF shows a heterogeneous surface 
where unreacted carboxyl groups provide the surface with hydrophilic 
properties and the linked diterpenes on the surface provide hydrophobic 
regions. This distribution of polarity provides our surfaces with imperfect 
amphipathicity, like that of biosurfactants (BS). BS are surface-active 
molecules produced by microorganisms with hydrophilic and hydrophobic 
moieties. According to the surface charge of their hydrophilic moiety, BS can 
be anionic, non-ionic, cationic, and amphoteric.121 They are mainly divided into 
glycolipids, lipoproteins, phospholipids and polymers.122 They exhibit their 
antimicrobial activity, primarily, by disrupting the plasma membrane or cell wall 
of bacteria.123 Rhamnolipids (RL, Figure 25) are glycolipid biosurfactants 
composed of a hydrophilic rhamnose moiety and a hydrophobic lipid tail linked 
by O-glycosidic linkage.124 They have been widely studied for their broad-
spectrum antimicrobial properties. RL have anionic charge at neutral pH and 






Figure 25 The structure of di-rhamnolipid (adapted form Kim et al. 2015). 
A recent study evaluated the antibacterial activity of 88 against S. aureus 
biofilms established on polystyrene plates using broth or skimmed milk as the 
growth media.125 The biofilm surface has charged groups, which promotes 
attractive or repulsive ionic interactions. In this study, the research group 
adjusted the solution of 88 to a neutral pH where the anionic form of 88 was 
dominant. The results revealed that RL activity depends on the biofilm matrix 
composition. RL disrupted 88.9% of the milk-based biofilm, probably due to 
the high carbohydrate content of milk-based biofilms. Biofilms grown in broth 
were less susceptible to 88, as the biofilm was reduced by only 35%. The 
study concluded that 88 reacts with carbohydrates and promotes their 
solubilization. 
Another study by Sotirova and colleagues investigated the effect of 88 on 
cell surface properties of P. aeruginosa NBIMCC 1390.126 The effect of the 
biosurfactant was measured at concentrations above the critical micelle 
concentration (CMC; 153.7 μM, 461.0 μM) and below CMC (76.8 μM). CMC 
is the concentration of the surfactants, above which, micelles form.127 Above 
CMC, the total LPS cellular content was reduced by 22%, while below CMC, 
LPS were not affected. Instead, the concentration of the outer membrane 
proteins (Opr F, Opr D, Opr J and Opr M) decreased. 
A study investigated the physicochemical interactions between 88 and P. 
aeruginosa at a concentration of 461.0 μM, close to the CMC value 368.8 μM 
of 88.124 The results revealed that the protein and the carbohydrate content of 
the EPS of the biofilm decreased by 79.6% and 31.6%. RL interacted 
selectively with different EPS proteins and led to the reduction of amide groups 
and N sources on the membrane. 
Similar to the anionic 88, our surfaces could react with positively charged 
residues and carbohydrates on bacterial cell wall and modulate their activity. 
However, changes in compounds bound to the surface of CNF affected the 
activity as 86 had weaker activity compared to 87. Thus, the spatial orientation 
of the bound molecules as well as the available functional groups participate 
in triggering the antibacterial activities. It is worth mentioning that compound 
85 was active against the Gram-positive strains only while 87 exhibited activity 
against both bacterial species. Our results proved that the mode of action of 
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unbound compounds is clearly different from their respective surfaces, which 
likely reflects their inability to permeate cell membranes when physically 
bound onto CNF. 
Our surfaces proved to be more active against Gram-positive S. aureus 
compared to Gram-negative E. coli. The main structural differences which 
distinguish Gram-positive bacteria from Gram-negative ones are a thicker 
peptidoglycan layer, the presence of teichoic acids and lipids and the absence 
of LPS.128 The LPS consists of the lipid A, the core oligosaccharide and the 
O-antigen.129 A study by Chaput and colleagues proved that the O-antigen 
neutralizes the negative charge of Gram-negative bacteria, which masks the 
charged residues required for charged antimicrobial peptides to exhibit 
activity.130 Thus, a potential suppressor of the activity of our surfaces towards 
Gram-negative bacteria could be the charge masking ability of O-antigen 
which hampers the reaction of our surfaces with the bacteria. Another reason 
could be the selectivity of our surfaces to certain surface proteins, which exist 
mainly in S. aureus strains. 
4.3 DESIGN AND SYNTHESIS OF 2,4,5,6-
TETRASUBSTITUTED PYRIMIDINES 
Biofilms form when microorganisms attach to surfaces, aggregate and form 
multicellular communities in a self-produced extracellular matrix.131,69 
Microorganisms form biofilms to protect themselves from environmental and 
chemical stresses. There are various problems associated with biofilm 
infections. Owing to their compact structure, biofilms are highly tolerant to the 
human immune response. They can also endure 10-1000-fold concentration 
of conventional antibiotics when compared to planktonic cells. For example, 
biofilms require a 600-fold increase in the concentration of chlorine, one of the 
most effective antibacterial agents, to be eradicated compared to planktonic 
cells. The rapid rise of antibacterial resistance combined with the lack of new 
antibiotic classes lead to hard-to-treat biofilm-related infections. 
Pyrimidines are heterocyclic nitrogenous aromatic compounds with wide 
occurrence in nature.132 As presented in the literature review, various studies 
have shown the relevance of pyrimidines in the development of new 
antibacterial agents. Aiming towards finding new antibacterial and anti-biofilm 
candidates, we screened a library of multi-substituted pyrimidines, against 
planktonic cells as well as against biofilm formation of S. aureus ATCC 25923 
at 400 μM (Publication III, Table S1). We identified the hit compound 89 which 
inhibited biofilm formation by 91% (Figure 26). Based on these findings, we 
designed and synthesized two sets of 2,4,5,6-tetrasubstituted pyrimidines and 







Figure 26 The chemical structure of the hit compound 89 and the inhibition percentage of the 
 bacterial viability of S. aureus ATCC 25923, at 400 μM. 
4.3.1 Design and synthesis 
 
Inspired by the hit molecule 89, we designed two sets of compounds. Our 
design focused on the chemical modification of C2, C4 and C6 positions of the 
pyrimidine core. The first set had different linear alkyl substituents in position 
C4 with different lengths (2, 4 or 8) or a 3-(trifluoromethyl)benzyl substituent. 
A free or a p-methoxyphenyl (PMP)-protected hydroxymethyl moiety in C2 and 
Cl, Br or OH in position C6. Guided by the bioactivity testing of the set I and 
aiming to enhance the potency, we synthesized a second set of compounds. 
All compounds of set II had free hydroxymethyl moiety in position C2. Position 
C4 had either and 1-heptyl or 1-nonyl ester and fluoride in C6 (Figure 27). The 




Figure 27 Design rationale of 2,4,5,6-tetrasubstituted pyrimidine scaffolds. 
As previously reported,133 we prepared compound 92 by reacting diethyl 
oxalpropionate (90) with 2-(4-methoxyphenoxy)acetamidine hydrochloride 
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(91), in the presence of triethylamine (TEA) in absolute ethanol. To assess the 
effect of different substituents on C4, we reacted 92 with different alcohols 
including 1-butanol, 1-heptanol, 1-octanol, 1-nonanol, or 3-
(trifluoromethyl)benzyl alcohol in the presence of a catalytic amount of sulfuric 
acid to make 93b-f. Except for 3-(trifluoromethyl)benzyl alcohol, the 
transesterification reaction yielded the disubstituted derivatives 94b–e as side 
products. To examine the effect of different halogens on C6, we reacted the 
intermediates 92 and 93b–f with phosphoryl bromide or phosphoryl chloride, 
in N,N-dimethylformamide (DMF) to yield 96a–e and 97a–f, respectively. 
Compound 97e was converted to 98e when stirred with KF and n-
tetrabutylammonium bromide (TBAB) in sulfolane, as previously reported.134 
Finally, the p-methoxyphenyl (PMP) protective group was removed by an 
oxidative cleavage reaction by stirring  94b–e and 96a–e, 97a–f, 98e, and with 
ceric ammonium nitrate (CAN) in MeCN/H2O to yield 95b, 95d, 99a–e, 89, 




Figure 28 Synthesis of 2,4,5,6-tetrasubstituted pyrimidines. Conditions: (I) TEA, EtOH, reflux, (II) 
 alcohol, H2SO4, 100 °C (III) POBr3, DMF, 90 °C, (IV) POCl3, DMF, 90 °C (V) KF, TBAB, 




4.3.2 EVALUATION OF THE ANTIBACTERIAL ACTIVITY 
To assess the activity of set I, we screened the compounds against the 
planktonic cells and prior-biofilm formation of S. aureus ATCC 25923, at 400 
μM (Table S1, Publication III). Azithromycin was used as a reference. None of 
the compounds was more active than 89. Of all the tested compounds, only 
95b and 99d were active. They caused 88.3% and 83.4% inhibition of biofilm 
viability in the pre-exposure mode, respectively. 
It was apparent that the PMP group did not contribute to the activity, as 
PMP-containing derivatives were all inactive. Replacing the Cl of 89 with Br 
decreased the activity. A plausible explanation is the difference in the electron-
withdrawing properties or the size of the halogens. Bromine is less 
electronegative and bigger in size than chlorine. 
Aiming to explore the structure-activity relationships (SAR) further, we 
designed and synthesized set II. As 89 and 99d have an octyl ester in C4, we 
investigated the effect of ±1 carbon on the activity by introducing 1-heptyl (99c, 
100c) or 1-nonyl (99e, 100e) in the same position. Fluorine is more 
electronegative and smaller than chlorine. We performed a chloride–fluoride 
replacement to assess its effect on the activity (101e). We tested 89, 95b and 
99d and our new set against two bacterial strains, S. aureus ATCC 25923 and 
S. aureus Newman at 100 μM. 
 
 
Table 9 The percentage of inhibition of bacterial viability of the most active compounds at 100 
 μM. 
Cmpds (100 μM) S. aureus ATCC 25923 S. aureus 
Newman  
Planktonic phase Biofilm pre-exposure Biofilm pre-
exposure 
Mean ±SD Mean ±SD Mean ±SD 
89 92.5 5.0 97.9 2.3 97.9 3.0 
99e 94.3 2.1 98.1 0.1 99.8 0.1 
100e 92.4 3.7 99.0 0.3 99.9 0.2 
Azithromycin 99.6 0.1 97.0 0.4 99.3 0.1 
 
Compounds exhibiting more than 50% inhibition in the pre-exposure assay 
are shown in Table 9. We identified 89, 99e and 100e as the most active 
compounds as they exhibited good activities toward both bacterial strains. 
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Compound 101e was devoid of activity compared to its analogue 89. The 
replacement of 1-octyl with a 1-nonyl group in C4 resulted in comparable 
activity for the chlorinated analogue 100e and enhanced activity for the 
brominated analogue 99e. It is worth mentioning that 99d showed a strain-
specific activity, as it inhibited the biofilm of S. aureus ATCC 25923 by 51.7% 
but was inactive against S. aureus Newman. 
We next explored the anti-biofilm potencies of 89, 99e and 100e by 
determining their IC50 values in pre- and post-exposure modes of both S. 
aureus strains. We also measured their MIC values against planktonic cells. 
As displayed in Table 10, the three compounds successfully prevented biofilm 
formation and reduced the viability of existing biofilms. The compound 99e 
was the most active with a MIC value 40 μM for both staphylococcal strains. 
Next, we calculated the logarithm of reduction of the viable cells caused by the 
three compounds at 100 μM, in both S. aureus strains. Both 99e and 100e 
displayed more than 2-log reductions while 89 displayed 3-log reductions 
(Figure 3, Publication III). 
 
Table 10 The potency of the most active compounds. 
 
Cmpds 
S. aureus ATCC 25923 S. aureus Newman 
Biofilms (IC50, μM) Planktonic 
bacteria 
Biofilms (IC50, μM) Planktonic 
bacteria 
Pre Post Folda MIC (μM) Pre Post Folda MIC (μM) 
89 23.6 54.9 2.3 60 38.4 62.0 1.6 60 
100e 16.8 51.8 3.1 60 37.3 44.8 1.2 60 
99e 11.6 23.3 2.0 40 29.4 31.9 1.1 40 
 
To assess whether the compounds have broad-spectrum activities, we 
tested them against two P. aeruginosa strains (ATCC 9027 and ATCC 15442) 
at 400 μM. The compounds were inactive against the tested Gram-negative 
strains as no significant reduction in viable cell counts was noticed after 24 h 
incubation. 
4.3.3 CYTOTOXICITY EVALUATION 
Unspecific cytotoxicity is a concern related to the development of new 
antibacterial agents. We tested our most active compounds against the human 
Hep2 cell line, at 100 μM (Table S3, Publication III). The compounds caused 
unspecific cytotoxicity when tested at 100 μM. However, when tested at 40 
μM, a comparable concentration to their pre-exposure IC50 values, 89, 99e 




4.3.4 STUDIES OF THE MECHANISTIC ACTION 
To elucidate the possible mechanism of action, we performed membrane 
permeability studies by incubating the pre-formed biofilms of S. aureus ATCC 
25923 with 89, 99e and 100e for 2 h. Fluorescence imaging showed that none 
of the compounds disrupted the membrane integrity, indicating that they bind 
to intracellular targets. 
The time-kill curve monitors the microbial viability in relation to the time and 
concentration of the antibacterial agent. We incubated different concentrations 
of 89 (0.5, 1 and 2 × the MIC value) with the viable cells of S. aureus ATCC 
25923 during an 8-h period. No decrease in bacterial growth was observed for 
½ × MIC and 1 × MIC during the 8-h incubation period. However, after 4 h, the 
compound exhibited a dose-dependent activity at 2 × MIC, decreasing the 
bacterial growth at a similar rate, comparable to that of azithromycin (Figure 
4, Publication III). These results agree with the fluorescence imaging as 
compounds that bind to intracellular bacterial targets require longer response 
times. 
This study highlights the value of pyrimidines as starting materials for the 
development of new antibacterial agents. Herein, we designed and 
synthesized new 2,4,5,6-tetrasubstituted pyrimidines and assessed their 
antimicrobial activities. We identified 89, 99e and 100e as the most potent anti-
biofilm agents as they effectively inhibited the biofilm formation and disrupted 
the established biofilms of two S. aureus strains. Our mechanistic studies 
showed that the compounds are slow-acting and that they do not target the 
bacterial membrane. Cytotoxic studies revealed that the compounds exhibited 
moderate cytotoxicity when tested against human Hep2 cells at concentrations 




5 SUMMARY AND CONCLUSIONS 
This thesis describes the design, synthesis and biological evaluation of 
antibacterial and anti-biofilm surfaces and compounds to target bacterial 
proliferation. Preventing the accumulation of microorganisms on surfaces 
limits the spread of infection. Drawbacks in the common strategies to design 
antibacterial surfaces include extreme complexity, the use of synthetic 
polymers and metal ions like silver, which are toxic to the environment. 
Our study focused on developing new environmentally friendly and 
effective antibacterial and anti-biofilm surfaces based on cellulose nanofibrils. 
We synthesized four materials, which were characterized and tested for their 
antibacterial activities toward E. coli, S. aureus and methicillin-resistant S. 
aureus. 
Our anionic materials showed clear and robust antimicrobial activity 
against all the tested bacterial strains. To establish their potential use in 
biomedical applications, we tested our most active material, 87 in both a 
biofilm and an artificial dermis model, which mimics the chronic wound 
environment. It successfully resisted bacterial colonization in both models. The 
biocompatibility studies showed that fibroblasts proliferated on the surface of 
87 better than they did on the biocompatible CNF. Furthermore, only very 
minor hemolysis (1.8%) was caused by this film. 
We speculate that the mechanism of action of our surfaces resemble that 
of the negatively charged biosurfactants. They bind to positively charged 
residues on the bacterial cell membrane and disturb them. Additionally, 
scanning electron micrographs showed damage to the cell wall of S. aureus 
after incubation with 87. The unbound compounds showed different 
antimicrobial activity compared to their respective surfaces. The remarkable 
biocompatibility combined with the robust potency of our materials suggest 
their potential use as part of advanced biomaterials. 
The WHO report on global surveillance of antimicrobial resistance states 
that antibiotic resistance is a real danger present in every continent. It is 
emerging faster than we are replacing current antibiotics. The most common 
strategy to develop new antimicrobial agents is to modify existing active 
analogues. As demonstrated in the literature review, resistance can occur to 
structurally similar compounds. Aiming to tackle this problem, we designed 
and synthesized a new set of 2,4,5,6-tetrasubstituted pyrimidines and tested 
them against planktonic cells and biofilms of S. aureus. 
We identified 89, 99e and 100e with the best antibacterial and anti-biofilm 
activities. They prevented biofilm formation and disrupted the already 
established biofilms with minimum inhibitory concentrations in the low 
micromolar range. Studies of the mechanistic action revealed that the 
compounds are slow-acting and that they do not target the bacterial cell wall. 




assayed at their pre-exposure IC50 values. Our study highlighted the value of 
pyrimidines as new interesting starting point for the development of small 
molecules to target resistant bacteria. Overall, our research illustrates 
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